Publications by Fredrik Hellem Schjesvold
30 publications found
Publications 2021
-
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann Hematol, 100 (1), 297-302
DOI 10.1007/s00277-020-04302-0, PubMed 33106909
Publications 2020
-
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann Hematol, 99 (8), 1793-1804
DOI 10.1007/s00277-020-04149-5, PubMed 32613281 -
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
Am J Hematol (in press)
DOI 10.1002/ajh.26083, PubMed 33368455 -
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
Lancet Oncol, 22 (1), 142-154
DOI 10.1016/S1470-2045(20)30680-X, PubMed 33301738 -
Melflufen for relapsed and refractory multiple myeloma
Expert Opin Investig Drugs, 29 (10), 1069-1078
DOI 10.1080/13543784.2020.1808884, PubMed 32924646 -
Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019
Eur J Haematol, 105 (4), 434-448
DOI 10.1111/ejh.13464, PubMed 32557833 -
Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial
Eur J Haematol, 104 (5), 443-458
DOI 10.1111/ejh.13379, PubMed 31880006 -
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma
Future Oncol, 16 (11), 631-641
DOI 10.2217/fon-2020-0024, PubMed 32141766 -
Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Haematologica (in press)
DOI 10.3324/haematol.2020.253450, PubMed 32586908 -
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
Haematologica, 105 (12), 2879-2882
DOI 10.3324/haematol.2019.240374, PubMed 33256392
Publications 2019
-
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Lancet, 394 (10214), 2096-2107
DOI 10.1016/S0140-6736(19)32556-5, PubMed 31735560 -
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
Lancet Oncol, 20 (6), e302-e312
DOI 10.1016/S1470-2045(19)30309-2, PubMed 31162104 -
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Lancet Haematol, 6 (9), e459-e469
DOI 10.1016/S2352-3026(19)30110-3, PubMed 31327687 -
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Lancet Oncol, 20 (6), 781-794
DOI 10.1016/S1470-2045(19)30152-4, PubMed 31097405 -
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Lancet Haematol, 6 (9), e448-e458
DOI 10.1016/S2352-3026(19)30109-7, PubMed 31327689
Publications 2018
-
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Lancet, 393 (10168), 253-264
DOI 10.1016/S0140-6736(18)33003-4, PubMed 30545780 -
Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
BMC Cancer, 18 (1), 801
DOI 10.1186/s12885-018-4722-x, PubMed 30089450 -
In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy
Blood, 132, 4676
DOI 10.1182/blood-2018-99-110357, PublikaID 304 -
Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
Blood, 132, 4677
DOI 10.1182/blood-2018-99-110669, PublikaID 303
Publications 2017
-
Immunologiske mekanismer for drap av kreftceller
Tidsskr Nor Laegeforen, 137 (1), 58
DOI 10.4045/tidsskr.16.0963, PubMed 28073239 -
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice
Leukemia, 31 (10), 2114-2121
DOI 10.1038/leu.2017.69, PubMed 28232741
Publications 2016
-
Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
Clin Microbiol Infect, 23 (3), 179-187
DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737
Publications 2015
-
Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens
Cancer Res, 75 (16), 3268-78
DOI 10.1158/0008-5472.CAN-14-3640, PubMed 26038231
Publications 2014
-
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Front Immunol, 5, 174
DOI 10.3389/fimmu.2014.00174, PubMed 24782871 -
Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells
Eur J Immunol, 44 (9), 2625-37
DOI 10.1002/eji.201444659, PubMed 24846412
Publications 2013
-
[Investigation of anemia]
Tidsskr Nor Laegeforen, 133 (6), 610
DOI 10.4045/tidsskr.13.0256, PubMed 23552139 -
[Investigation of amyloidosis]
Tidsskr Nor Laegeforen, 133 (3), 266
DOI 10.4045/tidsskr.13.0044, PubMed 23381155
Publications 2012
-
A woman in her seventies with reduced general condition, dyspnoea and generalised pain
Tidsskr Nor Laegeforen, 132 (17), 1969-72
DOI 10.4045/tidsskr.11.0608, PubMed 23007363
Publications 2009
-
[Erythrocytosis as a problem]
Tidsskr Nor Laegeforen, 129 (22), 2387; author reply 2387
DOI 10.4045/tidsskr.09.1196, PubMed 19935946
Publications 2008
-
[High-dose treatment of systemic AL-amyloidosis with autologous stem cell support]
Tidsskr Nor Laegeforen, 128 (12), 1392-6
PubMed 18552900